Stuttering Treatment Devices

Table of Contents

Coverage Policy ................................................... 1
Overview .............................................................. 1
General Background............................................ 1
Coding/Billing Information................................. 3
References ......................................................... 3

Related Coverage Resources

Speech Generating Devices
Speech Therapy

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Coverage Policy

Coverage for a stuttering treatment device varies across plans. Please refer to the customer’s benefit plan document for coverage details.

A stuttering treatment device is considered experimental, investigational or unproven.

Overview

This Coverage Policy addresses altered auditory feedback (AAF) devices for the treatment of stuttering.

General Background

Stuttering, also referred to as stammering or dysfluency, is a speech disorder in which the normal flow of speech is disrupted by frequent repetitions or prolongations of speech sounds, syllables or words, or by an individual’s inability to start a word. Developmental stuttering (DS) is the most common form of dysfluency and includes all cases that have gradual onset in childhood. Acquired stuttering in previously fluent individuals is much rarer than DS and may be neurogenic, resulting from brain damage associated with stroke or traumatic brain injury. Normal developmental dysfluency and early signs of stuttering are often difficult to differentiate. A speech evaluation is recommended for children who stutter longer than six months (Kirshner, 2008).
At present there is no cure for stuttering. Standard treatment for the disorder involves speech therapy with a variety of therapeutic approaches. Many programs for persistent stuttering focus on relearning how to speak or behavior modification. Treatment often includes educating parents about restructuring the child’s environment to reduce episodes of stuttering. In some cases, medications such as haloperidol or risperidone are used.

Altered auditory feedback (AAF) devices have been proposed as a treatment method. The rationale for AAF lies in the observation that individuals who stutter tend to become more fluent when speaking in unison with others, a phenomenon called the choral effect. Delayed auditory feedback (DAF) delays the user’s voice to his or her ears. Frequency-shifted auditory feedback (FAF) alters the pitch of the user’s voice in his or her ears. Masking auditory feedback (MAF) synthesizes a sine wave that imitates vocal fold vibration which facilitates the fluency of speech. The masking sound is triggered by a laryngeal microphone and played back to the user via an earpiece. The underlying mechanisms that enhance fluency under AAF have not been identified. Many theories have been proposed such as distraction, auditory malfunctioning, or modified vocalization.

**U.S. Food and Drug Administration (FDA)**
The FDA categorizes stuttering or antistammering devices as Class I devices. As such, these devices are exempt from premarket notification procedures. The FDA defines an antistammering device as one that electronically generates a noise when activated or when it senses the user’s speech and that is intended to prevent the user from hearing the sounds of his or her own voice. The device is used to minimize a user’s involuntary hesitative or repetitive speech (FDA, 2017). Trade names for antistammering devices include: SpeechEasy® (Janus Development Group Inc., Greenville, NC), Fluency Master (National Medical Equipment Inc., New Hyde Park, NY); and Pocket Speech Lab, SmallTalk and Basic Fluency System (Casa Futura Technologies, Boulder, CO).

**Stuttering Devices**
The SpeechEasy device utilizes DAF and FAF to recreate and optimize the choral effect. The device is worn like a traditional hearing aid. When wearing a SpeechEasy device the user’s words are digitally replayed in their ear with a very slight delay and frequency modification, which creates the illusion of speaking in unison with another person. This reportedly reduces stuttering in some individuals.

Auditory feedback provided by the Fluency Master antistuttering device involves the use of a small microphone placed near the larynx of the user. The microphone detects vocal tone vibrations which are amplified and sent to the user’s earpiece. It is proposed that the amplification of vocal tone by the Fluency Master helps to control stuttering and improve fluency.

The Pocket Speech Lab utilizes all three types of AAF. In addition, vocal tension biofeedback analyzes the voice frequencies and amplitudes of the user. A green light indicates vocal relaxation and changes to red with increased vocal tension. This technique aims to train the user to speak with relaxed breathing and control of the muscles involved in speech. The SmallTalk provides two types of altered auditory feedback, DAF and FAF with Bluetooth wireless technology and background noise reduction. The Basic Fluency System also uses DAF and FAF for fluency on and off the telephone with the option of adding a manual sine wave to mask auditory feedback (MAF).

**Literature Review**
A number of uncontrolled case studies (n=9–335) have reported on the clinical use and effectiveness of devices used for the treatment of stuttering (Foundas, et al., 2013; Ratyńska, et al., 2012; Unger, et al., 2012; Lincoln, et al., 2010; Armson and Kiefte, 2008; Stuart, et al., 2006; Armson, et al., 2006; Kalinowski, et al., 2004; Van Borsel, et al., 2004). Results of some studies have suggested that the use of these devices reduces stuttering frequency. However, the small sample sizes, short-term follow-up, and uncontrolled, nonrandomized design of these studies limit the generalizability of the results.

One randomized controlled trial (RCT) (n=20) conducted by Ritto et al. (2016) compared the effectiveness of an AAF (i.e., SpeechEasy) to behavioral techniques for stuttering. Participants were randomized to either be fitted with a SpeechEasy device without any supplementary fluency enhancing technique (n=11) or to get a 12-week fluency promotion protocol with techniques based on both fluency shaping and stuttering (n=7). The primary
outcome measure was the number of stuttered syllables. There was a 40% reduction in number of stuttered syllables from baseline measures, but no statistically significant differences (p>0.05) was found between groups up to six months of follow-up. These study results suggest AAF may be equivalent to behavioral techniques for stuttering. However the study is limited by the small sample size and short-term follow-up period.

Bothe et al. (2006) conducted a systematic review of the evidence for behavioral, cognitive, and related treatments for developmental stuttering. There were no articles identified in the literature published between 1970 and 2005 specific to the SpeechEasy device that met the trial quality inclusion criterion established for this analysis (Bothe, et al., 2006).

There is insufficient evidence in the published peer-reviewed scientific literature to conclude that stuttering devices are effective in the treatment of stuttering or dysfluency. Well-designed prospective RCTs are needed to establish the long-term efficacy of these devices and to define their role in the treatment of stuttering when compared to standard treatment (e.g., speech therapy), or no treatment.

**Professional Societies/Organizations**
According to the American Speech-Language-Hearing Association (ASHA), early findings indicate that auditory feedback devices may be helpful for some people, but not for others. ASHA states that research is ongoing to identify the following (ASHA, 2018):

- why some people benefit from the devices more than others
- whether the devices can be made to be more effective
- how much improvement one might expect in fluency when a device is used either alone or with speech therapy
- whether the benefits last over time

The National Institute on Deafness and other Communication Disorders (NIDCD) states that some people who stutter use electronic devices to help control fluency. However, questions remain about how long such effects may last and whether people are able to easily use these devices in real-world situations. For these reasons, researchers are continuing to study the long-term effectiveness of these devices (NIDCD, 2017).

**Use Outside of the US**
No relevant information.

**Coding/Billing Information**

**Note:** 1) This list of codes may not be all-inclusive.
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Experimental/Investigational/Unproven when used to report stuttering treatment devices:**

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E1399</td>
<td>Durable medical equipment, miscellaneous</td>
</tr>
</tbody>
</table>


**References**


